Please login to the form below

Not currently logged in
Email:
Password:

EC approves S-A/ BMS dual antiplatelet drug

Sanofi-aventis and Bristol-Myers Squibb have received EC approval for their dual antiplatelet combination tablet DuoPlavin/DuoCover

Sanofi-aventis (S-A) and Bristol-Myers Squibb (BMS) have received European approval for their dual antiplatelet combination tablet DuoPlavin/DuoCover (clopidogrel 75mg and acetylsalicylic acid 100mg or 75 mg) by the European Commission (EC).

DuoPlavin/DuoCover is a fixed dose combination medicine for the prevention of atherothrombotic events in adult patients already taking both clopidogrel (Plavix) and acetylsalicylic acid (ASA). 

The combination treatment is intended for continuation of therapy in non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention and for the treatment of ST-segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy.

Plavix (also produced by S-A and BMS) is recommended for daily use by patients who have had a recent heart attack or stroke, or have poor circulation in the legs that may cause pain during exercise, such as walking, and may be relieved by rest (known as peripheral artery disease, or PAD). 

Plavix is also recommended in addition to ASA for patients who have been hospitalised with heart-related chest pain (unstable angina) or have had a heart attack.

The new dual formulation has the added benefit of being a single tablet and therefore helps to reduce patients' daily pill burdens.

25th March 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Tree
Pharma’s vital role in sustainability and corporate social responsibility
Pharma is in the spotlight as tough questions about sustainability commitments continue to arise...
Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....